Why Regeneron’s CEO remains bullish on Eylea drug after 11 years on the market

"What's driving the category are demographics, aging of the population, as well as [an] increase in diabetes and diabetic eye disease," Regeneron CEO Len Schleifer said during the 41st annual J.P. Morgan Healthcare Conference in San Francisco.